{"organizations": [], "uuid": "708b054a0a54973d8c039b56ae4f8499088f61bb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-esperion-posts-qtrly-loss-per-shar/brief-esperion-posts-qtrly-loss-per-share-1-73-idUSASC09YYU", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Posts Qtrly Loss Per Share $1.73", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:49:00.000+03:00", "replies_count": 0, "uuid": "708b054a0a54973d8c039b56ae4f8499088f61bb"}, "author": "", "url": "https://www.reuters.com/article/brief-esperion-posts-qtrly-loss-per-shar/brief-esperion-posts-qtrly-loss-per-share-1-73-idUSASC09YYU", "ord_in_thread": 0, "title": "BRIEF-Esperion Posts Qtrly Loss Per Share $1.73", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "esperion therapeutics inc", "sentiment": "none"}, {"name": "esperion", "sentiment": "none"}, {"name": "esperion therapeutics", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "esperion therapeutics inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:50 AM / Updated 10 minutes ago BRIEF-Esperion Posts Qtrly Loss Per Share $1.73 Reuters Staff\nMay 2 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION\n* ESPERION THERAPEUTICS - ESTIMATES THAT CURRENT CASH RESOURCES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2020\n* ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $130 TO $140 MILLION AT DECEMBER 31, 2018\n* ESPERION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.73 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:49:00.000+03:00", "crawled": "2018-05-02T15:10:44.021+03:00", "highlightTitle": ""}